{
  "personality": null,
  "timestamp": "2025-10-30T04:42:12.956170",
  "category": "Health",
  "news_summary": "Breakthroughs in medical science showcase powerful new antibiotics, innovative spinal cord injury treatments, elimination of mother-to-child disease transmission in the Maldives, and effective brain training that reverses cognitive aging.",
  "news_summary_fr": "Les percées dans le domaine de la science médicale présentent de nouveaux antibiotiques puissants, des traitements innovants des lésions de la moelle épinière, l'élimination de la transmission des maladies de la mère à l'enfant aux Maldives et un entraînement cérébral efficace qui inverse le vieillissement cognitif.",
  "news_summary_es": "Los avances de la ciencia médica muestran nuevos y potentes antibióticos, tratamientos innovadores de lesiones medulares, la eliminación de la transmisión de enfermedades de madre a hijo en las Maldivas y un eficaz entrenamiento cerebral que revierte el envejecimiento cognitivo.",
  "articles": [
    {
      "title": "Scientists find hidden antibiotic 100x stronger against deadly superbugs",
      "summary": "A team of scientists discovered a hidden antibiotic 100 times stronger than existing drugs against deadly superbugs like MRSA. The molecule had been overlooked for decades in a familiar bacterium. It shows no signs of resistance so far, offering hope in the fight against drug-resistant infections and paving the way for new approaches to antibiotic discovery.",
      "content": "Chemists from the University of Warwick and Monash University have identified a promising new antibiotic that can combat drug-resistant bacterial infections, including MRSA and VRE.\n\nAntimicrobial resistance (AMR) is considered one of the most serious threats to global health. The World Health Organization (WHO) recently warned that there are \"too few antibacterials in the pipeline\" and that most easily discoverable antibiotics have already been found. Because developing new antibiotics is costly and offers limited financial reward, few pharmaceutical companies are investing in this critical area.\n\nDiscovery of a Hidden Antibiotic Intermediate\n\nIn a recent paper in the Journal of the American Chemical Society, researchers from the Monash Warwick Alliance Combatting Emerging Superbug Threats Initiative reported the discovery of a potent new antibiotic called pre-methylenomycin C lactone. The compound had been \"hiding in plain sight\" as an intermediate chemical in the natural process that produces the known antibiotic methylenomycin A.\n\nProfessor Greg Challis, co-lead author from the Department of Chemistry at the University of Warwick and the Biomedicine Discovery Institute at Monash University, explained: \"Methylenomycin A was originally discovered 50 years ago and while it has been synthesized several times, no-one appears to have tested the synthetic intermediates for antimicrobial activity! By deleting biosynthetic genes, we discovered two previously unknown biosynthetic intermediates, both of which are much more potent antibiotics than methylenomycin A itself.\"\n\nA 100-Fold Boost in Antibacterial Strength\n\nWhen tested, one of these intermediates -- pre-methylenomycin C lactone -- proved to be over 100 times more active against a range of Gram-positive bacteria than methylenomycin A. It was particularly effective against Staphylococcus aureus and Enterococcus faecium, the bacterial species responsible for Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE).\n\nCo-lead author Dr. Lona Alkhalaf, Assistant Professor at the University of Warwick, said: \"Remarkably, the bacterium that makes methylenomycin A and pre-methylenomycin C lactone -- Streptomyces coelicolor -- is a model antibiotic-producing species that's been studied extensively since the 1950s. Finding a new antibiotic in such a familiar organism was a real surprise.\"\n\nShe added that it appears S. coelicolor may have originally evolved to produce a strong antibiotic (pre-methylenomycin C lactone), but over time shifted toward making methylenomycin A, a weaker version that could serve a different biological role.\n\nEncouragingly, the research team found no evidence of bacterial resistance to pre-methylenomycin C lactone in Enterococcus under conditions that typically lead to resistance against vancomycin. Since vancomycin is often a \"last-resort\" treatment for these infections, this result is a particularly hopeful sign for addressing VRE, which the WHO lists as a high-priority pathogen.\n\nA New Direction for Antibiotic Discovery\n\nProfessor Challis noted: \"This discovery suggests a new paradigm for antibiotic discovery. By identifying and testing intermediates in the pathways to diverse natural compounds, we may find potent new antibiotics with more resilience to resistance that will aid us in the fight against AMR.\"\n\nThe next step in the development of the antibiotic will be pre-clinical testing. In a coordinated publication earlier this year in the Journal of Organic Chemistry, a team led by Monash collaborating with the Warwick team and funded by the Monash Warwick Alliance Combatting Emerging Superbug Threats initiative reported a scalable synthesis of pre-methylenomycin C lactone, paving the way for further research.\n\nProfessor David Lupton, School of Chemistry, Monash University who led the synthesis work says: \"This synthetic route should enable the creation of diverse analogues that can be used to probe the structure−activity relationship and mechanism of action for pre-methylenomycin C lactone. The Centre to Impact AMR at Monash gives us a great platform to take this promising antimicrobial forward.\"\n\nWith its straightforward chemical structure, strong antibacterial power, apparent resistance-proof profile, and scalable production process, pre-methylenomycin C lactone stands out as a promising new candidate. It could ultimately help save many of the estimated 1.1 million lives lost each year to antimicrobial resistance.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251029002855.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-29",
      "sentiment_score": 0.95,
      "reasoning": "The article reports the discovery of a new antibiotic compound that is 100 times stronger than existing drugs against deadly superbugs like MRSA and VRE, which are major global health threats. This discovery offers a significant breakthrough in combating antimicrobial resistance, a critical issue affecting millions worldwide. The research is detailed, describing the compound's origin, potency, lack of resistance development, and potential for scalable production, indicating a substantial positive impact on global health.",
      "category": "Health",
      "personality_title": "Scientists discover antibiotic 100 times stronger against deadly superbugs",
      "personality_presentation": "**Context** – Antibiotic resistance happens when bacteria no longer respond to medicines, making infections harder to treat. Dangerous bacteria like MRSA and VRE cause serious illnesses, and finding new antibiotics is becoming very difficult because most have already been discovered.\n\n**What happened** – Scientists from the University of Warwick and Monash University found a hidden antibiotic called pre-methylenomycin C lactone inside a common bacterium studied for decades. This new antibiotic is over 100 times stronger than a related drug called methylenomycin A and works well against bacteria that cause MRSA and VRE.\n\n**Impact** – This discovery is important because the new antibiotic is very powerful and so far, bacteria have not developed resistance to it. Since MRSA and VRE are often resistant to many treatments, this new antibiotic could help doctors fight infections that are currently very hard to cure.\n\n**What's next step** – Researchers will now carry out pre-clinical tests to study how the antibiotic works and how safe it is for people. They have also developed a way to produce it in larger amounts, which will help in future experiments and possible medicine development.\n\n**One-sentence takeaway** – Scientists have found a new, much stronger antibiotic hidden in a well-known bacterium that could help fight dangerous drug-resistant infections like MRSA and VRE.\n",
      "personality_title_fr": "Des scientifiques découvrent un antibiotique 100 fois plus puissant contre les super-bactéries mortelles",
      "personality_presentation_fr": "**Contexte** – La résistance aux antibiotiques survient lorsque les bactéries ne répondent plus aux médicaments, rendant les infections plus difficiles à soigner. Des bactéries dangereuses comme le SARM et l'ERV causent de graves maladies, et il devient de plus en plus difficile de trouver de nouveaux antibiotiques car la plupart ont déjà été découverts.\n\n**Ce qui s'est passé** – Des scientifiques des universités de Warwick et Monash ont découvert un antibiotique caché appelé pré-méthylénomycine C lactone dans une bactérie commune étudiée depuis des décennies. Cet antibiotique est plus de 100 fois plus puissant qu'un médicament apparenté, la méthylénomycine A, et fonctionne bien contre les bactéries responsables du SARM et de l'ERV.\n\n**Impact** – Cette découverte est importante car ce nouvel antibiotique est très puissant et, jusqu'à présent, les bactéries n'ont pas développé de résistance. Comme le SARM et l'ERV sont souvent résistants à de nombreux traitements, ce nouvel antibiotique pourrait aider les médecins à soigner des infections actuellement très difficiles à guérir.\n\n**Prochaine étape** – Les chercheurs vont maintenant effectuer des tests précliniques pour étudier comment l'antibiotique agit et s'il est sûr pour les humains. Ils ont aussi trouvé un moyen de le produire en grande quantité, ce qui facilitera les expériences futures et le développement de médicaments.\n\n**Phrase clé** – Des scientifiques ont trouvé un nouvel antibiotique beaucoup plus puissant caché dans une bactérie connue, qui pourrait aider à combattre des infections résistantes aux médicaments comme le SARM et l'ERV.\n",
      "personality_title_es": "Científicos descubren un antibiótico 100 veces más fuerte contra superbacterias mortales",
      "personality_presentation_es": "**Contexto** – La resistencia a los antibióticos ocurre cuando las bacterias ya no responden a los medicamentos, haciendo que las infecciones sean más difíciles de tratar. Bacterias peligrosas como el MRSA y el VRE causan enfermedades graves, y encontrar nuevos antibióticos es cada vez más difícil porque la mayoría ya han sido descubiertos.\n\n**Qué pasó** – Científicos de las universidades de Warwick y Monash encontraron un antibiótico oculto llamado pre-metilenomicina C lactona dentro de una bacteria común que se ha estudiado durante décadas. Este nuevo antibiótico es más de 100 veces más fuerte que un medicamento relacionado llamado metilenomicina A y funciona bien contra las bacterias que causan MRSA y VRE.\n\n**Impacto** – Este descubrimiento es importante porque el nuevo antibiótico es muy potente y, hasta ahora, las bacterias no han desarrollado resistencia a él. Como MRSA y VRE a menudo son resistentes a muchos tratamientos, este nuevo antibiótico podría ayudar a los médicos a combatir infecciones que actualmente son muy difíciles de curar.\n\n**Próximo paso** – Los investigadores realizarán pruebas preclínicas para estudiar cómo funciona el antibiótico y si es seguro para las personas. También han desarrollado una forma de producirlo en grandes cantidades, lo que ayudará en futuros experimentos y en el desarrollo de medicamentos.\n\n**Frase clave** – Científicos han encontrado un nuevo antibiótico mucho más fuerte oculto en una bacteria conocida que podría ayudar a combatir infecciones resistentes a los medicamentos como MRSA y VRE.\n",
      "image_url": "public/images/news_image_Scientists-find-hidden-antibiotic-100x-stronger-ag.png",
      "image_prompt": "A detailed, warm painting of a glowing, intricately shaped molecular structure representing pre-methylenomycin C lactone, radiating vibrant light that gently dissolves stylized, darkened shapes of resistant bacteria like MRSA and VRE, set against a soft, natural-toned scientific laboratory background with subtle abstract hints of chemical pathways and microscopic bacterial forms."
    },
    {
      "title": "Thiorphan reprograms neurons to promote functional recovery after spinal cord injury",
      "summary": "Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09647-yThiorphan is identified as a new and effective drug treatment for spinal cord injury that can be adopted across nervous system disease states in the development of new therapies for human neurological disorders.",
      "content": "We adopted a five-step pipeline to identify candidates for enhancing neural repair with a streamlined path that could lead to human testing (Fig. 1a). Step 1 involves characterizing the transcriptomic state or ‘signature’ of a cell type that exhibits a beneficial biological effect. In this case, we used the transcriptome of corticospinal motor neurons that are capable of regeneration after SCI. We reported previously that, within 2 weeks of SCI, the corticospinal neuron undergoes transient transcriptional reversion to an embryonic state—a state in which it is capable of regenerating1. These data are publicly available. In Step 2, we perform an in silico screen to compare the regenerating corticospinal transcriptome with shifts in the transcriptome generated by more than 1,300 small molecules or compounds in the Broad CMap (https://bioconductor.org/packages/release/data/experiment/html/ConnectivityMap.html). Drugs and small molecules in CMap have been exposed to various cell lines in vitro, and effects of these compounds on the transcriptome of the cultured cells have been characterized3. Thus, we searched CMap for compounds that generated transcriptomic shifts that parallel the state of regenerating corticospinal neurons. In Step 3, we took the lead candidates from the in silico screen and applied them to a medium-throughput in vitro assay consisting of cultures of adult motor cortex neurons; this screen became available only recently2 and provides what could be the most useful in vitro system for predicting potential in vivo effects in the mature nervous system, because the screen consists of adult rather than embryonic or postnatal neurons. To date, in vitro cellular screens of the nervous system consisted of either embryonic or early postnatal neuronal cultures, which may not accurately reflect responses of adult central nervous system (CNS) neurons. Immortalized neural cell lines4 suffer from similar limitations. Although adult dorsal root ganglia (DRG) neurons can be cultured routinely, these cells exhibit fundamentally different transcriptomes before and after injury1,5,6 and, again, might not be accurate tools for predicting therapeutic benefits of candidate therapies for injured brain and spinal cord motor neurons. Induced pluripotent stem cells or neurons induced from other cell types also often exhibit early cellular markers7. Cultures of adult neurons therefore may represent the most optimal in vitro screen developed for clinical translation2. Step 4 consists of in vivo validation of the top drug arising from the in vitro screen in a model of SCI. Finally, Step 5 consists of validating candidate compounds in cultures of adult primate cortical neurons, including human adult cortex. This step follows rather than precedes in vivo testing because of the scarcity of the primate and human neuronal resource: normal human neurons in particular are available only occasionally from surgical specimens and in our case were obtained from an individual undergoing tumour resection through a cortical window, where pathology confirmed the cortical biopsy was normal tissue.\n\nFig. 1: Drug discovery pipeline, in silico analysis and in vitro validation. a, Drug discovery pipeline consisting of five steps: (1) creation of a transcriptomic dataset; (2) in silico analysis using CMap; (3) medium-throughput in vitro screen; (4) in vivo testing of lead candidate(s); and (5) in vitro monkey and human validation. CST, corticospinal tract. b, In silico analysis shows ranking of compounds in CMap on the basis of connectivity score (left y axis), specificity score (blue, right y axis) and reliability score (green, right y axis) (see text for further detail). c, Neurite extension in composite image of cortical neurons treated with DMSO control and thiorphan (250 μM), Tuj1 labelling. d,e, In vitro screen of top three ‘hits’ from in silico screen, together with predicted negative modulator, adiphenine. Tested in cultures of adult mouse primary cortical neurons for 5 days in vitro, three independent biological replicates were performed on separate days, each using neurons from four adult mice. For each condition, data from all neurons measured across replicates were combined to yield n = 200 neurons per condition. Each neuron was spatially separated and analysed as an independent observation. Total neurite outgrowth per cell (Tuj1 labelling) is shown for each condition. Median values: DMSO (82.9); thiorphan (90.7, 99.8, 132.4, 166.1); triflusal (74.3, 61.7, 94.5, 124.5); milrinone (78.9, 77.4, 68.5, 75.5); adiphenine (74.4, 44.5, 31.7, 3) (d). Maximum neurite length per cell is shown for each condition. Median values: DMSO (93.3); thiorphan (111.1, 105.4, 122.1, 128); triflusal (84.4, 85, 104.9, 114.3); milrinone (100.6, 81.7, 79, 78.6); adiphenine (87.4, 60, 30.6, 6.23) (e). Statistical significance was determined by two-tailed Student’s t-test (**P < 0.01, ***P < 0.001). Error bars ± s.e.m. (d,e). Scale bar, 25 μm (c). Full size image\n\nCharacterizing the transcriptomic state\n\nStep 1 was accomplished in this study by using our previous data describing the transcriptome of the regenerating corticospinal neuron1, as referenced above.\n\nIn silico analysis\n\nIn silico analysis directly followed the original methodology of Lamb et al.3, identifying several compounds that most closely matched the expression profile of the regenerating corticospinal system (Fig. 1b and Supplementary Fig. 1a). A ‘connectivity score’ with a value between +1 and −1 described the similarity between the corticospinal transcriptomic profile and an individual compound’s transcriptomic profile, where +1 was most similar and −1 was least similar to the corticospinal dataset (Fig. 1b). We further calculated a ‘reliability score’ for each compound that takes into account the connectivity score, P value, false detection rate (FDR), ‘instance count’ (number of experiments that include the compound), non-null score (the ratio of experiments that have a consistent score based on most experiments) and ‘specificity score’ derived from the distribution of enrichment scores for gene lists from MSigDB; see Methods for a more detailed description of the reliability score. The top compounds that met the criteria of highest enrichment, reliability and specificity scores were considered ‘hits’ in this assay and included: quinostatin (highest enrichment score +0.91 ± 0.07), thiorphan (+0.86 ± 0.11), triflusal (+0.79 ± 0.13) and milrinone (+0.78 ± 0.18), whereas adiphenine was the most negatively correlated (−0.78 ± 0.18; Fig. 1b and Supplementary Fig. 1b). Biological annotation (Methods) indicated that quinostatin inhibits PI3 kinase; thiorphan is a neutral endopeptidase inhibitor; triflusal inhibits nuclear factor κB, phosphodiesterase and COX1, and milrinone is a phosphodiesterase inhibitor (Supplementary Fig. 1a). Quinostatin was not available for purchase and attempts at synthesis did not yield adequate quality compound. Thiorphan has been characterized primarily as a neutral endopeptidase inhibitor targeting neprilysin8. It has also been linked to neuroprotective properties in models of perinatal excitotoxic brain lesions9 and diabetic retinopathy10, and has β-amyloid degrading properties11. Thiorphan, milrinone and triflusal were taken forward as positive candidates, and adiphenine was used as a negative control.\n\nIn vitro adult motor cortical culture screen\n\nWe assessed the lead candidate compounds in dissociated cultures of the adult (postnatal day 60) mouse motor cortex2. An average of 10,000 neurons per single motor cortex were obtained, and we quantified total neurite outgrowth and maximal neurite length per cell 5 days after exposure to the candidate compounds. Several drug doses were applied (Fig. 1d,e), including the predicted negative modifier of corticospinal growth, adiphenine. Significant overall differences in neurite outgrowth were present using various compounds (drug type × dose interaction generalized estimating equation for total neurite outgrowth, Wald chi-square = 60.67, P < 0.0001; drug type × dose interaction generalized estimating equation for total maximum neurite length, Wald chi-square = 227.78, P < 0.0001). Thiorphan stood out as most effective both in measures of total neurite outgrowth and neurite length: at a dose of 250 μM it increased total neurite outgrowth by 80% compared with controls (post hoc generalized estimating equation, Wald chi-square = 29.69, P < 0.001; Fig. 1d,e) and longest neurite length by 30% (post hoc generalized estimating equation, Wald chi-square = 12.62, P < 0.001; Fig. 1d,e). The effect of thiorphan was dose dependent, with peak effects occurring at doses between 100 μM and 250 μM. The effect of the next candidate drug for enhancing corticospinal regeneration, triflusal, was more modest, with an increase in neurite outgrowth of 30% at its peak dose of 250 μM with no significant change in longest neurite length; none of these changes reached statistical significance (Fig. 1e). The third candidate in rank order, milrinone, did not significantly influence either total neurite outgrowth or longest neurite length at any dose (Fig. 1d,e). Validating the in silico screening process, the predicted negative regulator of corticospinal growth, adiphenine, strongly and significantly reduced total neurite outgrowth and longest neurite length in a dose-dependent manner (post hoc generalized estimating equation, P < 0.001; Fig. 1c–e).\n\nIn vivo testing in a model of SCI\n\nGiven the success of thiorphan in demonstrating efficacy in the in vitro screen, it advanced to Step 4: in vivo testing in a clinically relevant model of SCI. Adult Fischer 344 rats underwent severe contusive bilateral cervical SCI at the C5 spinal cord segment; mid-cervical lesions are the most common levels of human injury12 (Supplementary Fig. 2a,b). We then waited 2 weeks—a clinically relevant time to delay intervention to allow subject recovery from the acute effects of injury (Fig. 2a). Animals were then divided into one of four treatment groups: (1) lesion alone (n = 9), (2) thiorphan alone (n = 10), (3) diluent + NPC graft (n = 9) and (4) thiorphan + NPC graft (n = 9). We tested diluent + NPC grafts as a positive control in this lesion model because these cells support axonal regeneration into the lesion site, the formation of new neural relays across the injury site and partial functional recovery13,14. We also compared thiorphan alone with NPCs. The combination of thiorphan + NPCs aimed to determine whether effects of both treatments were additive, thereby representing a method of further augmenting recovery after severe cervical SCI. Thiorphan was infused continuously into the left motor cortex because it does not cross the blood–brain barrier. Infusions continued for 4 weeks starting 2 weeks after injury at a dose of 100 mM (0.25 μl h−1), based on extrapolation of in vitro dosing to in vivo dosing15. An in vivo neprilysin cleavage assay confirmed the bioactivity of intraparenchymal motor cortex infusions of thiorphan over 1, 2 and 4 weeks (Supplementary Fig. 2c). Spinal cord NPC grafts were obtained from Fischer 344 embryonic-day-14 (E14) spinal cords as reported previously16 and injected through the dura into the lesion cavity 2 weeks post SCI (Fig. 2b; Methods). Two weeks before euthanasia, the corticospinal projection was traced anterogradely using an AAV9-CAG–Ruby2sm_Flag.\n\nFig. 2: Thiorphan improves functional outcomes after severe C5 bilateral contusion. a, In vivo experimental outline of a clinically relevant SCI model. b, Nissl stain of a severe C5 bilateral contusion model. Sagittal section, rostral to left. Top, large contusion cavity in an ungrafted animal after 3 months. Bottom, NPC graft filling the lesion cavity and providing substrate for potential corticospinal axon regeneration. c, Skilled forelimb successful pellet retrieval with right paw on Montoya staircase23 ± s.e.m. Animals that received thiorphan and a substrate for axonal regeneration into the lesion site—an NPC graft—exhibit significant functional recovery over time compared with lesioned controls (P = 0.005, group × time interaction, Poisson generalized linear model). Treatment with thiorphan alone also trended towards significance (P = 0.14). The lesion model applied in this experiment is the most severe that we have tested, and NPC grafts also exhibited a trend towards better outcomes than lesioned controls but this did not reach statistical significance. Grey shading, period of thiorphan infusion into cortex. d, Thiorphan + NPC graft group also exhibits significant recovery of pellet retrieval accuracy in this severe lesion model (P = 0.001). Other treated groups trend towards improved outcomes compared with lesioned controls. Accuracy represents the number of pellets eaten divided by the number of pellets displaced plus the number of pellets eaten. *P < 0.05 (c,d). Scale bar, 500 μm. Source data Full size image\n\nTwelve weeks after SCI, animals treated with thiorphan + NPC grafts exhibited a significant, twofold improvement in forelimb grasping success (number of pellets grasped and eaten) after severe mid-cervical SCI compared with lesioned controls (Poisson generalized linear model, Wald chi-square = 7.92, P = 0.005; Fig. 2c). Recipients of thiorphan alone or NPC grafts alone exhibited lesser degrees of forelimb recovery compared with lesioned controls that did not reach statistical significance (Poisson generalized linear model, Wald chi-square = 2.16, P = 0.14 comparing thiorphan with lesion alone, and Wald chi-square = 2.07, P = 0.15 comparing grafts-only with lesion alone; Fig. 2c). The accuracy of pellet retrieval (percentage of pellets grasped that are eaten) also improved significantly in animals that received thiorphan + NPC grafts (Gamma generalized linear model, Wald chi-square = 10.13, P = 0.001) compared with lesioned controls (60% accuracy versus 30% accuracy; Fig. 2d). Thus, as suggested by in silico and subsequent in vitro screens, thiorphan significantly improves functional outcomes when combined with neural stem cell grafts to sites of SCI by enhancing the potency of NPC grafting.\n\nTo examine anatomical mechanisms underlying beneficial effects of thiorphan infusion on functional outcomes, we assessed corticospinal axon regeneration into stem cell grafts occupying the lesion site. Previously, we have shown that corticospinal axons regenerate into NPC grafts placed into sites of SCI and form synapses. Further, grafted NPC neurons extend axons from the lesion site to host neurons below the lesion and form synapses; consequently, new neural relays are formed across the lesion that support functional improvement13,16,17,18,19. In the present experiment, thiorphan significantly increased corticospinal regeneration into grafts by 60% (P < 0.05; Fig. 3a,c,e) compared with individuals that received NPC grafts alone (Fig. 3b,d,e and Supplementary Fig. 3a,b). Thiorphan administration in the absence of NPC grafts could not promote corticospinal regeneration into the lesion cavity because there was no cellular substrate onto which injured corticospinal axons could extend. Thin plane confocal microscopy showed colocalization of corticospinal axon terminals with synaptophysin apposed onto grafted neurons, indicating putative synapse formation from regenerating host axons to grafted neurons (Fig. 3f). Nearly all grafted animals in this experiment exhibited complete graft filling of the lesion cavity (Supplementary Fig. 4a,b). Cortical infusion of thiorphan over 4 weeks caused no damage or neuronal loss in the motor cortex (Supplementary Fig. 4c,d).\n\nFig. 3: Thiorphan increases corticospinal axonal regeneration. a, CST axons labelled anterogradely with Flag (red) show greater regeneration into E14 neural progenitor stem cell grafts (green (green fluorescent protein (GFP))) in animals with thiorphan cortical infusions. The white dotted line indicates the host–graft interface; the boxed region is shown at higher magnification in c. b, Fewer corticospinal axons regenerate into animals that did not receive thiorphan cortical infusions. The white dotted line indicates the host–graft interface; the boxed region is shown at higher magnification in d. c,d, Higher magnification views of the boxed regions in a (c) and b (d) showing regenerating corticospinal axons. e, Corticospinal regeneration into graft occupying lesion site is increased 1.6-fold in the presence of thiorphan infusion into the motor cortex (*P < 0.05, two-tailed t-test). In the absence of a graft, no host axons are present in the lesion site; non-grafted animals could not be quantified. f, Regenerating host corticospinal axons form putative synapses with grafted neurons, based on colocalization of regenerating CST (red) with synaptophysin (SYN, white) apposed to grafted neuron (GFP, green). DAPI in blue. Arrows indicate the exact orthogonal view intersection point, single plane. Scale bars, 500 μm (a,b); 200 μm (c,d); 5 μm (f). Source data Full size image\n\nWe also examined whether thiorphan treatment influenced corticospinal axonal sprouting above the lesion site: there were no significant differences in corticospinal axon density among the four animal groups (Supplementary Fig. 5a,b). Although thiorphan was administered into the motor cortex, we also examined whether there was a difference in the growth of serotonergic or sensory (calcitonin gene-related-peptide-labelled) axons into the graft; as expected, there was no difference between thiorphan + NPC graft and the diluent + NPC grafted groups (Supplementary Fig. 6a–f). We further examined whether thiorphan administration into the cortex influenced the host–graft glial border (glial fibrillary acidic protein immunoreactivity); it did not (Supplementary Fig. 7a–c). Finally, we examined whether thiorphan administration into the cortex affected graft differentiation: it did not (Supplementary Fig. 7d–k); as expected, neither did it affect graft-derived axon extension into the host (Supplementary Fig. 7l,m). Thus, beneficial effects of thiorphan administration were detectable on the corticospinal system to which it was targeted.\n\nTesting in primate systems\n\nThe final step in this process, Step 5, extended the clinical relevance of this work by determining whether thiorphan can also promote growth from adult primate motor cortex and human cortical neurons (Fig. 4a–c). This step is performed last because these samples—particularly normal human cortex samples—are highly valuable. Human participant approval was obtained for these procedures. Neurons were isolated from the monkey M1 motor cortex, dissociated and cultured, adapted from ref. 2, and treated with 100 μM thiorphan for 5 days in vitro (two replicates). These cultures are free of NPCs when assessed by markers such as Nestin and Sox2. Thiorphan treatment significantly increased total neurite outgrowth by 36% (P < 0.001) and maximum neurite length by 61% (P < 0.0001) compared with control conditions (Fig. 4a–c). We then proceeded to culture the human cortex: normal cortex from the middle temporal gyrus of a 56-year-old man was obtained from biopsy, the tissue was dissociated and neuronal cultures established (adapted from ref. 2; Supplementary Fig. 8). Treatment with 100 μM thiorphan for 5 days in vitro (Fig. 4d–f) resulted in a significant increase in total neurite outgrowth by 30.3% ± 7.3% (P < 0.0001) compared with control conditions. Thiorphan also exhibited a significant increase in longest neurite length by 23.0% ± 9.4% (P = 0.016) compared with controls. Thus, thiorphan retains biological activity when tested in monkey and human cortical cultures, exhibiting roughly 40% of the potency exhibited in rats in effects on total neurite outgrowth and 70% of the potency exhibited in rats in terms of longest neurite length.\n\nFig. 4: Thiorphan increases growth of monkey and human cortical neurons and induces pro-regenerative state. a, Thiorphan significantly increased total neurite outgrowth from primary cultures of adult cynomolgus macaque motor cortex labelled for Tuj (***P < 0.001, two-tailed t-test). Control cultures received DMSO. Each point represents the total neurite length of individual neurons. Samples were run as technical duplicates, with neurons cultured for 5 days. b, Thiorphan treatment also significantly increased the maximum neurite length per cell by 1.8-fold (****P < 0.0001, two-tailed t-test). c, Representative images of cultures of adult primate motor cortex treated with diluent or thiorphan. d, Thiorphan significantly increased total neurite outgrowth from primary cultures of normal 56-year-old human cortex neurons labelled for Tuj (****P < 0.0001, two-tailed t-test). Neurons cultured for 5 days. Each point represents the total neurite length of one neuron. e, Thiorphan treatment of human cortical neurons also significantly increased the maximum neurite length per cell (**P < 0.01, two-tailed t-test). f, Representative images of 56-year-old human cortical neurons in culture labelled for Tuj1. g, RNA sequencing was performed on cultures of adult primary motor cortex from rhesus monkeys treated for 5 days with thiorphan or vehicle (DMSO). A total of 177 genes changed ±1.5-fold on a log 2 scale. h, Gene ontology of these 177 genes demonstrates clear enrichment for developmental processes (Gene Ontology database24, https://doi.org/10.5281/zenodo.10536401). i, To identify in vivo mechanisms recruited by thiorphan treatment, rat brains were removed after 2 weeks of thiorphan infusion and compared with diluent-infused controls. Thiorphan treatment increased immunolabelling for both BDNF and phospho-AKT in the infused motor cortex, reflecting a shift to a state that is developmental and pro-regenerative. Scale bars, 20 μm (c,f). Scale bars, 25 μm, inset scale bars, 10 μm. Full size image",
      "url": "https://www.nature.com/articles/s41586-025-09647-y",
      "source": "Nature",
      "published": "2025-10-30",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a significant scientific breakthrough identifying thiorphan as an effective drug treatment that promotes neural repair and functional recovery after severe spinal cord injury (SCI). The research includes a comprehensive pipeline from in silico screening to in vivo testing in animal models and validation in primate and human neurons, demonstrating broad potential impact for neurological disorder therapies. The findings show measurable, meaningful improvements in motor function and neural regeneration, offering hope for SCI patients and advancing clinical treatment possibilities.",
      "category": "Health",
      "personality_title": "New drug thiorphan helps nerve cells heal after spinal cord injury",
      "personality_presentation": "**Context** – Spinal cord injury (SCI) often causes lasting damage to nerves, leading to problems with movement and feeling. Finding treatments that help nerve cells repair themselves has been very difficult.\n\n**What happened** – Scientists used a step-by-step process to find drugs that could help nerve cells regrow after SCI. They started by studying nerve cells that naturally try to repair themselves after injury. They then compared these cells’ activity to the effects of many drugs in a database. From this, they found thiorphan as a top candidate. Testing thiorphan on adult mouse nerve cells in the lab showed it helped nerve fibers grow longer. Next, they tested thiorphan in rats with spinal cord injuries. Rats treated with thiorphan and special nerve stem cells showed much better recovery in using their front paws. Finally, thiorphan was tested on nerve cells from monkeys and humans, where it also helped nerve fibers grow.\n\n**Impact** – This research is important because it shows thiorphan can reprogram adult nerve cells to a more growth-friendly state, helping them repair after serious injury. The combination of thiorphan with nerve stem cell grafts doubled the recovery of movement in rats. Testing in human nerve cells suggests this drug might work in people. This is one of the first drugs found to promote nerve repair through a clear, tested process from computer studies to animals and human cells.\n\n**What's next step** – Researchers will likely continue studying thiorphan to understand exactly how it works and test its safety in humans. They may also explore combining it with other treatments to improve recovery after spinal cord injuries and possibly other brain or nerve disorders.\n\n**One-sentence takeaway** – Thiorphan is a promising drug that helps nerve cells regrow and improves movement recovery after spinal cord injury, with positive results from lab studies to animal models and human cells.",
      "personality_title_fr": "Le nouveau médicament thiorphan aide les cellules nerveuses à guérir après une lésion de la moelle épinière",
      "personality_presentation_fr": "**Contexte** – Les lésions de la moelle épinière causent souvent des dommages durables aux nerfs, entraînant des problèmes de mouvement et de sensation. Trouver des traitements aidant les cellules nerveuses à se réparer est très difficile.\n\n**Ce qui s’est passé** – Des scientifiques ont utilisé un processus en plusieurs étapes pour trouver des médicaments pouvant aider les cellules nerveuses à repousser après une lésion. Ils ont d’abord étudié des cellules nerveuses capables de se réparer naturellement après une blessure. Ensuite, ils ont comparé l’activité de ces cellules avec les effets de nombreux médicaments dans une base de données. Ils ont identifié le thiorphan comme meilleur candidat. Testé sur des cellules nerveuses de souris adultes en laboratoire, le thiorphan a aidé les fibres nerveuses à pousser plus longtemps. Puis, testé chez des rats blessés à la moelle épinière, le thiorphan associé à des cellules souches nerveuses a nettement amélioré l’usage des pattes avant. Enfin, le thiorphan a été testé sur des cellules nerveuses de singes et d’humains, où il a aussi favorisé la croissance des fibres nerveuses.\n\n**Impact** – Cette recherche est importante car elle montre que le thiorphan peut reprogrammer les cellules nerveuses adultes dans un état qui favorise la croissance, aidant à leur réparation après une blessure grave. La combinaison avec des greffes de cellules souches nerveuses a doublé la récupération des mouvements chez les rats. Les tests sur des cellules humaines suggèrent que ce médicament pourrait fonctionner chez l’homme. C’est l’un des premiers médicaments découverts grâce à un processus clair allant de l’ordinateur aux animaux et aux cellules humaines.\n\n**Prochaine étape** – Les chercheurs vont probablement continuer à étudier le thiorphan pour comprendre son fonctionnement exact et tester sa sécurité chez l’homme. Ils pourraient aussi explorer son association avec d’autres traitements pour améliorer la récupération après des lésions de la moelle épinière ou d’autres troubles nerveux.\n\n**Résumé en une phrase** – Le thiorphan est un médicament prometteur qui aide les cellules nerveuses à repousser et améliore la récupération des mouvements après une lésion de la moelle épinière, avec des résultats positifs allant des études en laboratoire aux modèles animaux et aux cellules humaines.",
      "personality_title_es": "Nuevo fármaco thiorphan ayuda a las células nerviosas a sanar tras lesión de la médula espinal",
      "personality_presentation_es": "**Contexto** – Las lesiones de la médula espinal suelen causar daños duraderos en los nervios, provocando problemas de movimiento y sensación. Encontrar tratamientos que ayuden a las células nerviosas a repararse ha sido muy difícil.\n\n**Qué pasó** – Científicos usaron un proceso paso a paso para encontrar medicamentos que puedan ayudar a que las células nerviosas vuelvan a crecer tras una lesión. Primero estudiaron células nerviosas que se reparan solas después de una lesión. Luego compararon la actividad de estas células con los efectos de muchos medicamentos en una base de datos. Encontraron que thiorphan era un buen candidato. Probado en células nerviosas de ratones adultos en laboratorio, thiorphan ayudó a que las fibras nerviosas crecieran más. Después, lo probaron en ratas con lesiones en la médula espinal. Las ratas tratadas con thiorphan y células madre nerviosas recuperaron mucho mejor el uso de sus patas delanteras. Finalmente, probaron thiorphan en células nerviosas de monos y humanos, donde también ayudó a crecer las fibras nerviosas.\n\n**Impacto** – Esta investigación es importante porque muestra que thiorphan puede cambiar las células nerviosas adultas a un estado que favorece el crecimiento, ayudándolas a repararse tras una lesión grave. La combinación de thiorphan con injertos de células madre nerviosas duplicó la recuperación del movimiento en ratas. Las pruebas en células humanas sugieren que este medicamento podría funcionar en personas. Es uno de los primeros medicamentos encontrados mediante un proceso claro que va desde estudios por computadora hasta animales y células humanas.\n\n**Próximo paso** – Los investigadores seguirán estudiando thiorphan para entender cómo funciona y probar su seguridad en humanos. También podrían explorar combinarlo con otros tratamientos para mejorar la recuperación tras lesiones de la médula espinal y otros trastornos nerviosos.\n\n**Resumen en una frase** – Thiorphan es un medicamento prometedor que ayuda a las células nerviosas a crecer y mejora la recuperación del movimiento tras una lesión de la médula espinal, con resultados positivos desde estudios de laboratorio hasta modelos animales y células humanas.",
      "image_url": "public/images/news_image_Thiorphan-reprograms-neurons-to-promote-functional.png",
      "image_prompt": "A detailed, warm painting of a vibrant neural network shaped like intertwined golden branches glowing softly within a gentle, abstract representation of a spinal cord, with bright, delicate sprouts emerging from the branches symbolizing regrowth and healing, set against a calm, natural-toned background that evokes hope and recovery."
    },
    {
      "title": "Maldives sets a global milestone by ending mother-to-child transmission of HIV, syphilis, and hepatitis B",
      "summary": "BY THE OPTIMIST DAILY EDITORIAL TEAM In a major step forward for public health, the Maldives achieved what no other country has done before: it has eliminated mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B. Recognized by the World Health Organization (WHO), this accomplishment marks the world’s first verified case of “triple elimination,” offering […]\nThe post Maldives sets a global milestone by ending mother-to-child transmission of HIV, syphilis, and hepatitis B first appeared on The Optimist Daily: Making Solutions the News.",
      "content": "BY THE OPTIMIST DAILY EDITORIAL TEAM\n\nIn a major step forward for public health, the Maldives achieved what no other country has done before: it has eliminated mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B. Recognized by the World Health Organization (WHO), this accomplishment marks the world’s first verified case of “triple elimination,” offering hope and a roadmap to other nations.\n\nThe achievement is the result of years of coordinated effort across the island nation’s healthcare system. “The Maldives has set an extraordinary example of what is possible with committed leadership, universal healthcare access, and integrated maternal services,” WHO said in its announcement.\n\nProactive care from the start\n\nCentral to the Maldives’ success is its strong maternal and neonatal healthcare infrastructure. More than 95 percent of pregnant women in the country receive full prenatal care, including early and routine screenings for HIV, syphilis, and hepatitis B. This ensures timely interventions, including immediate vaccination of newborns against hepatitis B within 24 hours of birth, followed by a complete immunization schedule.\n\nOfficial data from the Maldives Ministry of Health shows striking results. In both 2022 and 2023, no infants were born with HIV or syphilis. A 2023 national survey also confirmed that no child entering primary school was infected with hepatitis B. These are not just numbers. They represent lives untouched by preventable illnesses.\n\nA standout in a challenging region\n\nThis achievement becomes even more significant when viewed in context. Across Southeast Asia in 2024, approximately 23,000 pregnant women were diagnosed with syphilis, resulting in nearly 8,000 infants born with the disease. Another 25,000 women needed antiretroviral therapy to prevent HIV transmission to their babies, and more than 42 million people in the region are currently living with hepatitis B.\n\nThat makes the Maldives’ success not just admirable, but urgently instructive.\n\nLessons in integration and access\n\nHealth experts point to the country’s integrated approach as a key driver of progress. Instead of treating each disease as a separate issue, the Maldives embedded testing and treatment into routine maternal and child healthcare services. This seamless model helped close gaps in care and reduce stigma around testing and treatment.\n\nEqually vital has been the nation’s commitment to universal health coverage. All prenatal services, diagnostic tests, and vaccinations are provided free of charge, ensuring no expectant mother is left behind due to cost barriers.\n\nChallenges ahead, and a call to sustain progress\n\nWhile the recognition from WHO is a cause for celebration, it also comes with responsibility. WHO emphasized the need for continued vigilance. The Maldives must now focus on improving its digital health systems, reaching migrant and remote communities, integrating private healthcare providers, and maintaining stringent lab testing standards.\n\nStill, this accomplishment lights the way for other nations looking to safeguard the health of future generations. With vision, investment, and inclusive care, what the Maldives has achieved may one day become the global norm.",
      "url": "https://www.optimistdaily.com/2025/10/maldives-sets-a-global-milestone-by-ending-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b/?utm_source=rss&utm_medium=rss&utm_campaign=maldives-sets-a-global-milestone-by-ending-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b",
      "source": "The Optimist Daily: Making Solutions the News",
      "published": "2025-10-29",
      "sentiment_score": 0.95,
      "reasoning": "The Maldives has achieved a groundbreaking public health milestone by eliminating mother-to-child transmission of HIV, syphilis, and hepatitis B, verified by WHO. This accomplishment has broad significance as it offers a replicable model for other countries, especially in regions with high disease burdens. The article provides detailed context on the integrated healthcare approach, universal access, and measurable outcomes, demonstrating substantial positive real-world impact on maternal and child health.",
      "category": "Health",
      "personality_title": "Maldives becomes first country to stop mother-to-child transmission of three major infections",
      "personality_presentation": "**Context** – The Maldives is a small island nation in South Asia facing health challenges like many countries. Diseases such as HIV, syphilis, and hepatitis B can pass from mothers to their babies during pregnancy or birth, causing serious illness in children.\n\n**What happened** – The Maldives has become the first country in the world to completely stop the passing of HIV, syphilis, and hepatitis B from mothers to their babies. This achievement was officially confirmed by the World Health Organization (WHO) after careful checks. It happened thanks to years of strong healthcare efforts, including early testing and treatment for pregnant women and vaccinations for newborns.\n\n**Impact** – This is important because it shows that with good planning and care, it is possible to protect babies from these infections. In nearby countries, many babies still get sick from these diseases every year, so the Maldives’ success offers a clear example for others to follow. The country’s approach combined tests and treatments into regular healthcare visits, making it easier and free for all mothers to get care.\n\n**What’s next step** – The Maldives will keep working to improve healthcare services by using better technology, reaching harder-to-access communities, and including private doctors in their programs. WHO says it’s important to keep careful testing and support so the progress continues.\n\n**One-sentence takeaway** – The Maldives has shown that it is possible to stop three serious infections from passing from mothers to babies through strong, accessible healthcare.\n",
      "personality_title_fr": "Les Maldives, premier pays à éliminer la transmission mère-enfant de trois infections majeures",
      "personality_presentation_fr": "**Contexte** – Les Maldives sont un petit pays insulaire d’Asie du Sud confronté à des problèmes de santé similaires à d’autres pays. Des maladies comme le VIH, la syphilis et l’hépatite B peuvent être transmises de la mère à l’enfant pendant la grossesse ou l’accouchement, causant des maladies graves chez les enfants.\n\n**Ce qui s’est passé** – Les Maldives sont devenues le premier pays au monde à arrêter complètement la transmission du VIH, de la syphilis et de l’hépatite B de la mère à l’enfant. Cette réussite a été officiellement confirmée par l’Organisation mondiale de la santé (OMS) après des vérifications minutieuses. Cela a été possible grâce à des années d’efforts en santé publique, incluant des tests précoces et des traitements pour les femmes enceintes ainsi que la vaccination des nouveau-nés.\n\n**Impact** – C’est important car cela montre qu’avec une bonne organisation et des soins adaptés, il est possible de protéger les bébés contre ces infections. Dans les pays voisins, beaucoup d’enfants tombent encore malades chaque année à cause de ces maladies. Le succès des Maldives offre donc un exemple clair à suivre. Leur approche a intégré les tests et traitements dans les soins de santé habituels, rendant les soins gratuits et accessibles à toutes les mères.\n\n**Prochaine étape** – Les Maldives continueront à améliorer leurs services de santé en utilisant de meilleures technologies, en atteignant les communautés difficiles d’accès et en incluant les médecins privés dans leurs programmes. L’OMS souligne l’importance de maintenir des contrôles rigoureux et un soutien continu.\n\n**Conclusion en une phrase** – Les Maldives ont démontré qu’il est possible d’empêcher la transmission de trois infections graves de la mère à l’enfant grâce à un système de santé fort et accessible.\n",
      "personality_title_es": "Maldivas se convierte en el primer país en eliminar la transmisión madre a hijo de tres infecciones importantes",
      "personality_presentation_es": "**Contexto** – Maldivas es una pequeña nación insular en el sur de Asia que enfrenta desafíos de salud similares a otros países. Enfermedades como el VIH, la sífilis y la hepatitis B pueden transmitirse de la madre al bebé durante el embarazo o el nacimiento, causando enfermedades graves en los niños.\n\n**Qué pasó** – Maldivas se convirtió en el primer país del mundo en detener completamente la transmisión del VIH, la sífilis y la hepatitis B de madres a bebés. La Organización Mundial de la Salud (OMS) confirmó oficialmente este logro tras una revisión detallada. Esto fue posible gracias a años de esfuerzos en el sistema de salud, incluyendo pruebas y tratamientos tempranos para las mujeres embarazadas y vacunación para los recién nacidos.\n\n**Impacto** – Esto es importante porque demuestra que con buena organización y atención médica es posible proteger a los bebés de estas infecciones. En países cercanos, muchos bebés aún se enferman cada año por estas enfermedades, por lo que el éxito de Maldivas es un ejemplo claro para otros. Su método integró pruebas y tratamientos en las visitas médicas normales, haciendo que la atención sea gratuita y accesible para todas las madres.\n\n**Próximo paso** – Maldivas seguirá mejorando sus servicios de salud usando mejor tecnología, llegando a comunidades difíciles de alcanzar e incluyendo a médicos privados en sus programas. La OMS dice que es importante mantener controles estrictos y apoyo continuo.\n\n**Conclusión en una frase** – Maldivas ha demostrado que es posible detener la transmisión de tres infecciones graves de madre a hijo gracias a un sistema de salud fuerte y accesible.\n",
      "image_url": "public/images/news_image_Maldives-sets-a-global-milestone-by-ending-mother-.png",
      "image_prompt": "A serene island landscape of the Maldives at dawn, with gentle waves embracing a mother’s silhouette formed by flowing water and light, cradling three glowing orbs symbolizing HIV, syphilis, and hepatitis B being shielded and fading away; soft, natural tones of blues, greens, and warm pastels create a hopeful and nurturing atmosphere."
    },
    {
      "title": "Online brain training reverses 10 years of aging in memory and learning",
      "summary": "A new McGill-led study reveals that digital brain exercises can rejuvenate aging brain systems responsible for learning and memory. Older adults using BrainHQ for 10 weeks showed restored cholinergic function — effectively turning back the brain’s clock by a decade. Scans confirmed measurable biochemical changes, offering a hopeful new approach for dementia prevention.",
      "content": "A clinical trial led by McGill University has become the first in humans to demonstrate that online brain training can strengthen the brain networks responsible for learning and memory.\n\nAfter 10 weeks of using the game-like app BrainHQ, older adults showed significant improvements in cholinergic function, a key brain chemical system that tends to decline with age and affects attention, memory, and decision-making.\n\n\"The training restored cholinergic health to levels typically seen in someone 10 years younger,\" said senior author Dr. Etienne de Villers-Sidani, an Associate Professor in McGill's Department of Neurology and Neurosurgery and neurologist at The Neuro (Montreal Neurological Institute-Hospital).\n\n\"This is the first time any intervention, drug or non-drug, has been shown to do that in humans,\" he said.\n\nBecause Alzheimer's disease is linked to sharp declines in cholinergic health, the results help explain previous findings that such exercises can lower dementia risk and enhance cognitive performance. The researchers suggest this type of brain training could serve as a safer alternative to medication or work effectively alongside it.\n\nEvidence-based brain game\n\nBrainHQ features speed-based cognitive games that adapt to become more demanding as users improve, an approach supported by hundreds of scientific studies.\n\n\"A lot of people assume crossword puzzles or reading are enough to keep the brain sharp. But not all activities truly promote neuroplasticity,\" said de Villers-Sidani.\n\nSince BrainHQ is already commercially available, clinicians can discuss it with patients who want to take an active role in maintaining or improving brain health, he added.\n\nCutting-edge brain imaging at The Neuro\n\nTo observe brain changes, researchers used a specialized PET scan and tracer that makes cholinergic reserves visible, allowing them to measure activity before and after the training period.\n\n\"We used a rare technology,\" said de Villers-Sidani. \"The Neuro is one of the few centres worldwide that can produce the tracer and run the scan.\"\n\nThe study included 92 healthy adults aged 65 and older. Participants were randomly assigned to either the BrainHQ program or an active control group that played recreational computer games. Both groups trained on tablets for 30 minutes a day over 10 weeks, but only the BrainHQ users showed measurable increases in cholinergic activity.\n\nResearchers are now preparing a follow-up study to evaluate the program's effects in individuals with early-stage dementia.\n\nAbout the Study\n\n\"Effects of Computerized Cognitive Training on Vesicular Acetylcholine Transporter Levels using Fluoroethoxybenzovesamicol Positron Emission Tomography in Healthy Older Adults: Results from the INHANCE Randomized Clinical Trial\" by Mouna Attarha and Etienne de Villers-Sidaniet al. is published in JMIR Serious Games.\n\nThe study was conducted independently by McGill researchers in collaboration with Posit Science, which provided access to BrainHQ. All data collection and analyses were led by McGill.\n\nThis research was supported by the National Institute on Aging of the National Institutes of Health. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251029002858.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-29",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant clinical trial demonstrating that online brain training can reverse age-related decline in memory and learning by restoring cholinergic brain function, effectively turning back the brain's clock by a decade. This breakthrough has broad implications for aging populations worldwide and offers a promising, non-pharmaceutical approach to dementia prevention, supported by measurable biochemical evidence and advanced imaging techniques. The study is well-detailed, focused, and impactful for public health.",
      "category": "Health",
      "personality_title": "Online brain training restores memory function in older adults by 10 years",
      "personality_presentation": "**Context** – As people get older, their brains often lose some ability to remember and learn new things. This is partly because certain brain chemicals, like those in the cholinergic system, decrease with age. Finding ways to improve brain health in older adults is important to help prevent conditions like dementia.\n\n**What happened** – A study led by McGill University tested an online brain training program called BrainHQ. For 10 weeks, 92 adults aged 65 and over used the program for 30 minutes a day. BrainHQ offers games that get harder as players improve. Researchers used special brain scans to measure changes in the brain’s cholinergic system before and after the training.\n\n**Impact** – The study found that BrainHQ users had their cholinergic brain function restored to levels usually seen in people 10 years younger. This is the first time any treatment, drug or non-drug, has shown this effect in humans. Since cholinergic health is important for memory and attention and declines in Alzheimer’s disease, this training could help lower the risk of dementia.\n\n**What's next step** – Researchers plan to study how BrainHQ affects people with early dementia. Because the program is already available, doctors may recommend it to patients who want to improve brain health safely, either alone or alongside medication.\n\n**One-sentence takeaway** – A 10-week online brain training program has been shown to reverse 10 years of decline in memory-related brain function in older adults.",
      "personality_title_fr": "L'entraînement cérébral en ligne restaure la mémoire des personnes âgées de 10 ans",
      "personality_presentation_fr": "**Contexte** – En vieillissant, le cerveau perd souvent une partie de sa capacité à mémoriser et à apprendre, notamment parce que certains produits chimiques cérébraux diminuent. Trouver des moyens d'améliorer la santé du cerveau chez les personnes âgées est essentiel pour prévenir des maladies comme la démence.\n\n**Ce qui s'est passé** – Une étude menée par l'Université McGill a testé un programme d'entraînement cérébral en ligne appelé BrainHQ. Pendant 10 semaines, 92 adultes de 65 ans et plus ont utilisé le programme 30 minutes par jour. BrainHQ propose des jeux qui deviennent plus difficiles à mesure que les joueurs progressent. Les chercheurs ont utilisé des scanners spéciaux pour mesurer les changements dans le système cholinergique du cerveau avant et après l'entraînement.\n\n**Impact** – L'étude a montré que les utilisateurs de BrainHQ ont retrouvé une fonction cérébrale cholinergique équivalente à celle de personnes 10 ans plus jeunes. C’est la première fois qu’un traitement, médicamenteux ou non, montre cet effet chez l’humain. Comme la santé cholinergique est importante pour la mémoire et l’attention, et qu’elle diminue dans la maladie d’Alzheimer, cet entraînement pourrait aider à réduire le risque de démence.\n\n**Prochaine étape** – Les chercheurs prévoient d’étudier l’effet de BrainHQ chez les personnes atteintes de démence débutante. Comme le programme est déjà disponible, les médecins pourraient le recommander aux patients souhaitant améliorer leur santé cérébrale en toute sécurité, seul ou avec des médicaments.\n\n**Conclusion en une phrase** – Un programme d'entraînement cérébral en ligne de 10 semaines a permis de rajeunir de 10 ans la fonction cérébrale liée à la mémoire chez les personnes âgées.",
      "personality_title_es": "Entrenamiento cerebral en línea restaura la memoria en adultos mayores por 10 años",
      "personality_presentation_es": "**Contexto** – A medida que las personas envejecen, sus cerebros suelen perder parte de la capacidad para recordar y aprender, en parte porque ciertos químicos cerebrales disminuyen. Encontrar formas de mejorar la salud cerebral en adultos mayores es importante para prevenir enfermedades como la demencia.\n\n**Qué pasó** – Un estudio dirigido por la Universidad McGill probó un programa de entrenamiento cerebral en línea llamado BrainHQ. Durante 10 semanas, 92 adultos de 65 años o más usaron el programa 30 minutos al día. BrainHQ ofrece juegos que se vuelven más difíciles a medida que los usuarios mejoran. Los investigadores usaron escáneres especiales para medir cambios en el sistema colinérgico del cerebro antes y después del entrenamiento.\n\n**Impacto** – El estudio encontró que los usuarios de BrainHQ restauraron la función cerebral colinérgica a niveles que normalmente se ven en personas 10 años más jóvenes. Esta es la primera vez que un tratamiento, con o sin medicamentos, muestra este efecto en humanos. Como la salud colinérgica es clave para la memoria y la atención, y disminuye en la enfermedad de Alzheimer, este entrenamiento podría ayudar a reducir el riesgo de demencia.\n\n**Próximos pasos** – Los investigadores planean estudiar cómo BrainHQ afecta a personas con demencia en etapa temprana. Como el programa ya está disponible, los médicos podrían recomendarlo a pacientes que quieran mejorar su salud cerebral de forma segura, solos o junto con medicamentos.\n\n**Conclusión en una frase** – Un programa de entrenamiento cerebral en línea de 10 semanas ha demostrado revertir 10 años de declive en la función cerebral relacionada con la memoria en adultos mayores.",
      "image_url": "public/images/news_image_Online-brain-training-reverses-10-years-of-aging-i.png",
      "image_prompt": "A warm, detailed painting of an abstract human brain composed of interconnected glowing neural pathways that brighten and thicken over time, with a stylized tablet displaying evolving geometric patterns symbolizing adaptive brain training, all rendered in soft, natural earth tones and gentle light to evoke renewal and cognitive vitality."
    }
  ]
}